Ticker · CUSIP 00091F304

ABVC

ABVC BIOPHARMA INC
···Share
Holders (tracked)
2
Combined shares
169,806
Combined value
$361.7K
Last close
$1.32
Quarter
2025Q4
Price · 1Y$1.32+0.47 (+54.39%)H $4.74 · L $0.83 · Avg Vol 180K
Position opened
$1.00$2.00$3.00$4.00VolJul 25Oct 25Jan 26Apr 26
Tracked holders · last 8 quarters
-1 vs previous quarter over the last 7.
212023Q32025Q4
Price is -38.0% vs the avg quarter-end implied price across tracked holders.

SEC event timeline

5 events
  1. +39,879 shares · 2025Q4
    Position
  2. −19,603 shares · 2025Q4
    Position
  3. +3,763 shares · 2025Q4
    Position
  4. +19,603 shares · 2025Q3
    Position
  5. +68,794 shares · 2025Q3
    Position

Insider activity

No insider transactions in the last 30 days.
Follow-the-investor returns
If you'd copied each holder of ABVC…
Cost basis inferred from each manager's quarter-over-quarter position changes. Sorted by % return on the position they're still holding.
InvestorFirst inCost basisReturnPosition value today
Ken Griffin (Citadel Advisors)2023Q3$1.78-26.0%$73K
Renaissance Technologies2023Q4$2.38-44.5%$151K

Who moved on this name in 2025Q4

Position changes reported for the latest quarter, grouped by direction.
New positions0
Trimmed0

Institutional ownership over time

Distinct super-investors holding this ticker · combined dollar value, by quarter.
QuarterHoldersCombined value
2023Q3
1
$16K
2023Q4
2
$74K
2024Q2
1
$20K
2024Q4
1
$24K
2025Q2
1
$93K
2025Q3
3
$443K
2025Q4
2
$362K

Who owns ABVC

2 super-investors · 2025Q4
Tracked stake
169.8K
shares
Combined value
$362K
% of shares outstanding
shares-out unknown
Quarter action mix
Added2
#ManagerSharesValue
1Renaissance Technologies114.3K$243K
2Ken Griffin
Citadel Advisors
55.5K$118K

Recent moves

8 transactions
Embed this chart
Paste this iframe anywhere to embed the live ABVC chart.
<iframe src="https://openstocks.me/embed/stocks/ABVC" width="100%" height="480" frameborder="0" loading="lazy" title="ABVC chart by OpenStocks" style="border:0;border-radius:12px;background:transparent"></iframe>
Explore related topics